Invest In Exclusive Pre-IPO Biotech Companies Not Available To The Public
BioTech has outperformed the S&P every year for 20 years
Off-Market Pre-IPO Deals Not Available to the Public
Diversify with 20+ High Upside BioTech Companies
BioWise Capital Has Never Lost Investor Capital
HOW IT WORKS
Highest Annual Returns of all the VC investments
Significantly outperforms the S&P 500
OUR UNIQUE MARKET EDGE
We have access to pre-IPO opportunities not available to the public.
We invest inseed and series A which gives us the most equity per dollar invested.
We get entry below 50% valuation, which isn't possible with public stocks.
Our deals are extensively vetted with months of due diligence.
Our founder has an extensive medical background and 11 years of experience in private equity.
Tax codes IRC 1202 and 1045 may help prevent capital gains tax.
WHY NOW
Growing demand for global healthcare solutions post-COVID
We are expecting at least one exit in the next 9-12 month range (3rd quarter 2022)
BIOWISE’S HOLDINGS
OUR STRATEGY
Seed capital companies
Existing cash flowing entities
CAPITAL REQUIREMENTS TOTAL RAISE
$20
MINIMUM INVESTMENT
$100K
INCENTIVES
Special Shares For $250k+ Investments
FINANCIAL PROJECTIONS
8.2x In 5 Years
MEET THE FOUNDER
MEET THE FOUNDER
MEET THE TEAM
Nathaniel Dodson
Strategic advisor
Extensive experience in securities law, financial compliance, and corporate structuring
Advisor to multiple funds, private equity groups, and syndications
Completed his bachelors in Economics at UT Austin and his JD at USD
Jeff Stephens
Strategic advisor
+5 years identifying investment vehicles, actively spotting companies for acquisition and exit strategies.
Co-founder and general partner of Infusion 51a L.P., a healthcare investment fund, and Vivacitas Oncology Inc., a biopharmaceutical company focused on tough-to-treat cancers.
Scott Vandermeer
MBA / Strategic advisor
+5 years of experience financing both private and public micro-cap biopharmaceutical companies.
Instrumental development and expansion of Infusion 51a portfolio since its foundation (2015).
Co-founder and general partner of Infusion 51a L.P. and Vivacitas Oncology Inc.
Apply to Invest With US
frequently asked questions
As a healthcare professional who’s been in the industry for the past almost 20 years, I realize the value of technology.
People usually assume that the future where technology and healthcare fuse together is still a long way off, and for now, it’s just a hall mark for science fiction.
In reality, that future is much closer than most people think.
Sure, the pharmaceutical markets are making great strides, and so are the medical aid and health administration sectors.
They’ll always be relevant.
You’ll always be able to invest in them and more likely than not expect high, consistent returns.
But sooner rather than later, they’ll be taking a backseat to biotech.
Biotech is the future for healthcare.
But want to know what the problem with biotech is?
It’s a huge market, with huge potential, one of the largest markets expected to boom in the coming years…
…but it’s open only to such a select few.
The market today is valued at $793 billion…
It’s projected to grow by an extra $140.8 billion this year alone….
….and is expected to reach $1,600 billion by just 2030.
This is a huge, essential market, that has only been growing more and more traction since the pandemic, reaching more than a 10% annual growth rate.
A huge, essential market that is closed to a majority of investors.
I’ve been in the healthcare industry for decades, and if you aren’t an institutional investor, then you’ve essentially got no options to invest in.
And this is bottlenecking progress in the industry.
There are dozens of biotechs out there with huge potential, but they’re stuck in a rut and are unable to bootstrap or scale their technology because of a lack of funding.
Most institutional buyers don’t care about how the money machine they’re operating affects the world;
They just care about the returns they’re getting, and the time they’re getting it.
And they don’t want to share the pie.
Physicians and other experts in the field who’ve spent decades as I have, even they can’t invest.
They probably know the market better than anyone else, but they can’t invest.
They can’t invest because they simply don’t have the time, resources, or funds to find these quality companies that could change healthcare, and change the medical world, as we know it.
And that’s where BioWise comes in.
I saw the potential in the industry, in so many companies, and the only thing stopping them in their tracks is the lack of funding.
I decided that it was time to open the market up, both for the benefit of investors, and the benefit of the companies, industry, and world.
With our first fund alone we were able to invest in more than 16 biotechs AND get our investors returns of up to 300%….
….in just 4 years.
Our funds have the best of both worlds:
We’re giving back to healthcare, we’re bootstrapping life-changing technology
AND we’re getting our investors healthy returns and benefits with almost 0 risk.
That’s what we do with our funds.
We offer investors exclusive deals at a steep discount because of our extensive knowledge and expansive networks, and we do all the work.
And if that’s the change you want to see in the world, if these are the deal terms and returns you’d like to see on your money, then you know what to do.